Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
Black Diamond Therapeutics (Nasdaq: BDTX) has announced that its President and CEO, David M. Epstein, Ph.D., will give a presentation on the company’s advancements at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14, 2022, at 10:00 a.m. ET. Interested parties can access a live webcast of the discussion through the investor relations section of Black Diamond's website. The company specializes in precision oncology and is focused on developing novel MasterKey therapies for patients with genetically defined cancers.
- None.
- None.
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Canaccord Genuity Horizons in Oncology Virtual Conference being held on Thursday, April 14, 2022 at 10:00 a.m. ET.
A live webcast of the panel discussion can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the panel discussion will also be available and archived on the site for 90 days.
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Julie Seidel
investors@bdtx.com
For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com
FAQ
When is David M. Epstein presenting for Black Diamond Therapeutics?
How can I access the Black Diamond Therapeutics conference presentation?
What is the focus of Black Diamond Therapeutics?
What is the ticker symbol for Black Diamond Therapeutics?